Application | Comment | Organism |
---|---|---|
medicine | PSA kinetics differ significantly following different radiotherapy methods. A higher radiobiological efficiency of brachytherapy in comparison to external-beam radiotherapy (with a total dose of 70.2 Gy) in respect of normal prostate tissue (lower PSA nadir for patients without biochemical failure) and malignant prostate cells (lower PSA failure rate). PSA bounces occur predominantly in the first three years after treatment, particularly after low-dose-rate-brachytherapy | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
additional information | malignant and normal prostate cells | Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
prostate-specific antigen | - |
Homo sapiens |
PSA | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
physiological function | PSA bounces are found predominantly in the low-dose-rate-brachytherapy group (42% vs. 23%/20% after high-dose-rate-brachytherapy/external-beam radiotherapy). More patients reach a PSA lower than 0.5 ng/ml after brachytherapy in comparison to external-beam radiotherapy already after 12 months. The percentage increases in the following years, the majority of patients present with a PSA more than 0.2 ng/ml 36 months after brachytherapy | Homo sapiens |